The $1.75M award builds on a $5.5M grant from MJFF announced earlier this month. MapLight also received an $8.1M award from MJFF in 2020.

SAN FRANCISCO, CA, Aug. 25, 2021 – MapLight Therapeutics announced a $1.75M million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new therapies for the treatment of this debilitating disease. The project aims to identify non-dopaminergic drug combinations that will lower patients’ risk of developing L-DOPA-induced dyskinesia (LID) and enable the treatment of symptoms not traditionally addressed by dopamine replacement therapy, such as altered posture and balance.

“This additional funding from The Michael J. Fox Foundation supports exciting new work using our proprietary platform to discover novel therapeutic combinations for the treatment of Parkinson’s disease,” said Anatol Kreitzer, Ph.D., Chief Discovery Officer at MapLight. “We are honored to partner with an organization that shares our vision of innovation for the treatment of Parkinson’s Disease.”

L-DOPA, a dopamine replacement therapy, is the most prescribed therapeutic for providing Parkinson’s patients relief from motor symptoms, such as tremor and slow movement. However, long-term use and use in patients with advanced Parkinson’s disease can cause an imbalance of the neural pathways that activate and inhibit movement, leading to dyskinesia — involuntary movements that can be as debilitating as the disease itself.

The funded project, “Preclinical validation of combination therapies for Parkinson’s disease,” explores the potential that selective pharmacological targeting of dysregulated brain circuits can treat disease symptoms that have so far proven intractable.


About MapLight Therapeutics

MapLight Therapeutics is developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders. Today, there are few therapeutic options for people living with conditions such as Autism Spectrum Disorder, Parkinson’s Disease, and Schizophrenia, and those therapies are limited by modest efficacy and significant side effects. MapLight is committed to redefining this standard of care. The company’s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and treat those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of such groundbreaking technologies as optogenetics and STARmap. Learn more at




Media Contact for MapLight Therapeutics
Lauren Davis, Alkali Marketing, 512-751-2946